CONTACT: BECKY SOGLIN
2130 Medical Laboratories
Iowa City IA 52242
(319) 335-6660; fax (319) 335-8034
Release: May 10, 2000
UI invites women to participate in third cervical cancer vaccine study
IOWA CITY, Iowa -- Women ages 16 to 23 are invited to participate in a University
of Iowa Health Care clinical trial to help determine the effectiveness and
safety of a vaccine for a type of human papillomavirus (HPV).
The trial is the third in a series of HPV vaccine clinical trials being
conducted at the UI. HPV is associated with most cases of cervical cancer.
Women interested in participating in the trial must be in general good health
and must not be pregnant or planning to conceive while enrolled in the study,
which will last approximately seven months. Participants must be willing to
make approximately 10 visits to the UI Family Planning Clinic at the UI Hospitals
and Clinics. During these visits, they will receive the vaccine or a placebo.
Follow-up includes up to three years of gynecological exams that will test
for the presence of HPV infection or precancerous cells. In addition, routine
gynecologic care, contraception and compensation will be provided.
An effective cervical cancer vaccine will likely include several HPV strains
to ensure protection against all strains, said Kevin A. Ault, M.D., UI assistant
professor of obstetrics and gynecology, and the study's lead investigator.
Several other clinical trials are under way in the United States and abroad.
For more information, call Tracy Peters, UI research nurse, at (319) 356-2719
and ask about the HPV vaccine trial.
University of Iowa Health Care describes the partnership between the
UI College of Medicine and the UI Hospitals and Clinics and the patient care,
medical education and research programs and services they provide.